Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

12 Sep 2013
Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

10 Sep 2013
Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

10 Sep 2013
Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

7 Sep 2013
Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

5 Sep 2013
FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

5 Sep 2013
UCLA researchers receives $13M Early Translational grants to advance innovative discoveries using stem cells

UCLA researchers receives $13M Early Translational grants to advance innovative discoveries using stem cells

4 Sep 2013
Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

3 Sep 2013
Stem cell researchers receive Early Translational research awards from CIRM

Stem cell researchers receive Early Translational research awards from CIRM

30 Aug 2013
CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

From Cell Signaling Technology 28 Aug 2013
FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA grants Priority Review designation to sNDA for Nexavar tablets

27 Aug 2013
Powerful new option for treating vasculitis

Powerful new option for treating vasculitis

27 Aug 2013
Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

26 Aug 2013
Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

26 Aug 2013
Athera Transfers Annexin A5 Project To Medirista

Athera Transfers Annexin A5 Project To Medirista

23 Aug 2013
Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

22 Aug 2013
Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

20 Aug 2013
Omeros announces financial results for second quarter of 2013

Omeros announces financial results for second quarter of 2013

12 Aug 2013
Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

6 Aug 2013
Bayer Collaboration Could Net $540M+ For Compugen

Bayer Collaboration Could Net $540M+ For Compugen

6 Aug 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback